Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Purdue's Pain And No Gain: More Analysis Of OxyContin Postmarket Studies Needed

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA cancels advisory committee once Purdue pulls sNDA, but firm plans to resubmit after 'building the most compelling body of epidemiological evidence' that reformulated product has meaningful impact on abuse.

Advertisement

Related Content

Valbenazine FDA Panel Cancellation Is A Good Sign, Neurocrine Says
FDA Rebukes Egalet's Reliance On OxyContin Postmarketing Data

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS078649

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel